AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

When AbbVie spun off from Abbott in 2013, the writing was already on the wall for its autoimmune disease drug Humira losing exclusivity. Not only did Humira rank as AbbVie's top-selling product ...

With equity markets in shambles due to President Donald Trump's trade policies, now might be as good a time as any to invest in excellent dividend stocks. For one, dividend-paying companies tend to be ...

Humira is a treatment for moderate to severe rheumatoid arthritis, the first of six disease indications it has received en route to becoming Abbott's most successful product ever. Abbott acquired ...

Humira's exclusivity in the United States ... The streak dates back to its years as part of Abbott Laboratories. AbbVie began trading in 2012 following its spinoff from Abbott.